Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis

Federico Alberici, Rona M Smith, Mariana Fonseca, Lisa C Willcocks, Rachel B Jones, Julia U Holle, Stefan Wieczorek, Thomas Neumann, Davide Martorana, Gina Gregorini, Renato A Sinico, Annette Bruchfeld, Iva Gunnarsson, Sophie Ohlsson, Bo Baslund, Vladimir Tesar, Zdenka Hruskova, Maria C Cid, Augusto Vaglio, Paul Lyons, Kenneth Smith & David Jayne
Rituximab is effective at inducing and maintaining remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The wide interpatient variability in the duration of B-cell depletion and time to relapse as well as the significant relapse risk after treatment, costs, and adverse event rates necessitate improved patient stratification.
This data repository is not currently reporting citations. For information on how your repository can report citations, please see our documentation.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.